Literatura científica selecionada sobre o tema "Drug-sparing regimen"
Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos
Consulte a lista de atuais artigos, livros, teses, anais de congressos e outras fontes científicas relevantes para o tema "Drug-sparing regimen".
Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.
Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.
Artigos de revistas sobre o assunto "Drug-sparing regimen"
Rosa, Rossana, Jose F. Suarez, Marco A. Lorio, Michele I. Morris, Lilian M. Abbo, Jacques Simkins, Giselle Guerra et al. "Impact of antiretroviral therapy on clinical outcomes in HIV+ kidney transplant recipients: Review of 58 cases". F1000Research 5 (21 de dezembro de 2016): 2893. http://dx.doi.org/10.12688/f1000research.10414.1.
Texto completo da fonteDutta, Noton K., Abdullah Alsultan, Thomas J. Gniadek, Deborah A. Belchis, Michael L. Pinn, Khisimuzi E. Mdluli, Eric L. Nuermberger, Charles A. Peloquin e Petros C. Karakousis. "Potent Rifamycin-Sparing Regimen Cures Guinea Pig Tuberculosis as Rapidly as the Standard Regimen". Antimicrobial Agents and Chemotherapy 57, n.º 8 (3 de junho de 2013): 3910–16. http://dx.doi.org/10.1128/aac.00761-13.
Texto completo da fonteRuzicka, Daniel J., Mayuko Kamakura, Naho Kuroishi, Nobuyuki Oshima, Miyuki Yamatani, Jingbo Yi, Bruce Crawford, Kunihisa Tsukada e Shinichi Oka. "Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan". PLOS ONE 17, n.º 6 (14 de junho de 2022): e0269779. http://dx.doi.org/10.1371/journal.pone.0269779.
Texto completo da fonteMaggiolo, Franco, Nicola Gianotti, Laura Comi, Elisa Di Filippo, Laura Fumagalli, Silvia Nozza, Laura Galli, Daniela Valenti, Marco Rizzi e Antonella Castagna. "Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial". Antiviral Therapy 26, n.º 3-5 (maio de 2021): 51–57. http://dx.doi.org/10.1177/13596535211042226.
Texto completo da fonteSleeper, Rebecca B. "Antipsychotic Dose-Sparing Effect with Addition of Memantine". Annals of Pharmacotherapy 39, n.º 9 (setembro de 2005): 1573–76. http://dx.doi.org/10.1345/aph.1g207.
Texto completo da fonteTiberi, Simon, Marie-Christine Payen, Giovanni Sotgiu, Lia D'Ambrosio, Valentina Alarcon Guizado, Jan Willem Alffenaar, Marcos Abdo Arbex et al. "Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB". European Respiratory Journal 47, n.º 4 (10 de março de 2016): 1235–43. http://dx.doi.org/10.1183/13993003.02146-2015.
Texto completo da fonteFischl, Margaret A., Ann C. Collier, A. Lisa Mukherjee, Judith E. Feinberg, Lisa M. Demeter, Pablo Tebas, Marina Giuliano et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen". AIDS 21, n.º 3 (janeiro de 2007): 325–33. http://dx.doi.org/10.1097/qad.0b013e328011ddfa.
Texto completo da fonteKaroney, Mercy Jelagat, Mathew Kirtptonui Koech, Evangeline Wawira Njiru e Willis Dixon Owino Ong’or. "Proximal tubular renal dysfunction among HIV infected patients on Tenofovir versus Tenofovir sparing regimen in western Kenya". PLOS ONE 17, n.º 9 (15 de setembro de 2022): e0273183. http://dx.doi.org/10.1371/journal.pone.0273183.
Texto completo da fonteStürmer, Martin, Schlomo Staszewski e Hans Wilhelm Doerr. "Quadruple Nucleoside Therapy with Zidovudine, Lamivudine, Abacavir and Tenofovir in the Treatment of HIV". Antiviral Therapy 12, n.º 5 (julho de 2007): 695–704. http://dx.doi.org/10.1177/135965350701200514.
Texto completo da fonteKovalskaya, Galina N., Dina Y. Zhukova e Ekaterina N. Mikhalevich. "Interaction of Drugs Used for the Treatment of Cardiovascular Diseases". Acta Biomedica Scientifica 4, n.º 1 (4 de abril de 2019): 36–42. http://dx.doi.org/10.29413/abs.2019-4.1.6.
Texto completo da fonteTeses / dissertações sobre o assunto "Drug-sparing regimen"
Papot, Emmanuelle. "Coût des traitements antirétroviraux : évaluation de l’impact d’interventions au niveau des prescripteurs et des patients : ANRS-GOTA : Gestion Optimale des Traitements Antirétroviraux". Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5253.
Texto completo da fonteAbstract in English:Objectives: The main objective of this project was to evaluate the impact of a series of interventions, addressed to prescribers and patients, on the expenditure on antiretroviral therapies (ART) prescribed in the Department of Infectious and Tropical Diseases (SMIT) of the Bichat Hospital, Paris, France. The secondary objectives included the description of the antiretroviral regimens used, their price, the assessment of the knowledge, beliefs and representations regarding the price of ART, and the acceptability of such interventions, among prescribers and people living with HIV (PWH). At inception, an objective was also to monitor the sustainability of the immuno-virological response for PWH who benefited from an ART switch for economic reasons, and the absence of side effects or of an alteration of the healthcare giver-PWH relationship. Background: In 2014, the economic crisis led the French Health Insurance (Social Security) to pay more attention to the expenses generated by medicines free of charge, which included ART. Generic antiretrovirals came onto the French market, and the guidelines included the concept of ART optimisation for PWH in therapeutic success. This adaptation aimed to increase the comfort of ART intake and to decrease long-term side effects. It also tackled cost criteria, thus, introducing new challenges in the doctor-PWH relationship. Problem: With some information and actions on the proper use of ART, is it possible to curb the increase in ART expenditure without a negative impact on the effectiveness and tolerance of the treatment or on the healthcare giver-PWH relationship? Methods: An interventional before-after study, in order to evaluate the expenditure on ART before and after a series of interventions in the SMIT of Bichat, against control, was developed. The budget impact analysis and therapeutic success evaluation were supplemented with a psychosocial evaluation component based on focus groups with the prescribers and PWH of the SMIT of Bichat, and questionnaires administered to these two populations aiming at studying their perceptions around ART and their price, as well as their experience of these interventions. Results: The 2014 budget impact study at the Bichat site estimated the ARV budget at €48,280,200 and highlighted potential antiretroviral combinations that could be switched to cheaper combinations, with equal efficiency and tolerance, and adapted to the medical profile of PWH. Protease inhibitor (PI) regimens changed to drug-sparing regimen or PI-free regimens, moreover with generic antiretrovirals, were the scenarios with the largest impact in terms of budget reduction. Focus groups (organised in 2015) and questionnaires (administered in 2016) helped identify the themes of the interventions. After consultation of a group of PWH followed up at the SMIT, their healthcare givers and PWH associations, two interventions were developed (a shared-decision making guide on the choice of ART and their price, and a website calculating the price of ART). They were implemented in 2018 in the experimental site. Discussion and conclusion: The generalisability of the interventions developed and of the results of the “pre-interventions assessment” stage was discussed at a national and global level. Subsequently, the post-interventions assessment was affected by the COVID-19 pandemic. Directly, through the mobilisation of people in the fight against COVID-19, and indirectly because of the resulting public health crisis and the resilience of populations. This new context makes any comparison or observation obsolete. ANRS-GOTA was a pilot study in one site, its design, tools and interventions, created and implemented, could however be rolled-out for testing on a larger scale
Livros sobre o assunto "Drug-sparing regimen"
Harper, Lorraine, e David Jayne. The patient with vasculitis. Editado por Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0160.
Texto completo da fonteJayne, David. Treatment of ANCA-associated vasculitis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132.
Texto completo da fonteCapítulos de livros sobre o assunto "Drug-sparing regimen"
Pappas, Peter G. "Fungal Infections in Solid Organ Transplant Recipients". In Clinical Mycology, 470–87. Oxford University PressNew York, NY, 2003. http://dx.doi.org/10.1093/oso/9780195148091.003.0031.
Texto completo da fonteJayne, David. "Treatment of ANCA-associated vasculitis". In Oxford Textbook of Rheumatology, 1103–12. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0132_update_001.
Texto completo da fonte